


The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A compound of formula I



in which

R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R2 is hydrogen or 1-4C-alkyl,

R3 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,

R6 is -T1-Q1, in which

T1 is a bond, or 1-4C-alkylene,

Q1 is Ar1, Aa1, Hh1, or Ah1, in which

Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, or 4N-(1-4C-alkyl)-piperazino,

or

T2 is 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen, and

R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which

Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which

R6111 is halogen, or 1-4C-alkyl,

R6112 is 1-4C-alkyl, and

R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which

Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, 4N-(1-4C-alkyl)-piperazino, imidazolo, pyrrolo or pyrazolo,

R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,


Aa1 is a bisaryl radical made up of two aryl groups, which are independently selected from the group consisting of phenyl and naphthyl, and which are linked together via a single bond,

Hh1 is a bisheteroaryl radical made up of two heteroaryl groups, which are independently selected from the group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond,

Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from the group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from the group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond,

R7 is hydroxyl, or Cyc1, in which

Cyc1 is a ring system of formula Ia



in which

A is C (carbon),


B is C (carbon),

R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,  
 R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,  
 M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which  
 Ar2 is a benzene ring,  
 Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,  
 or a salt thereof.

2. (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
 R2 is hydrogen or 1-4C-alkyl,  
 R3 is hydrogen or 1-4C-alkyl,  
 R4 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
 R5 is hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,  
 R6 is -T1-Q1, in which  
 T1 is a bond, or 1-4C-alkylene,  
 Q1 is Ar1, Aa1, Hh1, or Ah1, in which  
 Ar1 is phenyl, or R61- and/or R62-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 T2 is a bond, 1-4C-alkylene, or 2-4C-alkylene interrupted by oxygen,  
 R611 is hydrogen, 1-4C-alkyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which  
 Har1 is optionally substituted by R6111 and/or R6112, and is a monocyclic or fused bicyclic 5- to 10-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, in which  
 R6111 is halogen, or 1-4C-alkyl,  
 R6112 is 1-4C-alkyl,  
 R612 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl or hydroxy-2-4C-alkyl,  
 R62 is 1-4C-alkyl, 1-4C-alkoxy, halogen, cyano, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylcarbonylamino, or 1-4C-alkylsulphonylamino,  
 Aa1 is a bisaryl radical made up of two aryl groups, which are independently selected from the group consisting of phenyl and naphthyl, and which are linked together via a single bond,  
 Hh1 is a bisheteroaryl radical made up of two heteroaryl groups, which are independently selected from the group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and which are linked together via a single bond,

- Ah1 is a heteroaryl-aryl radical or an aryl-heteroaryl radical made up of a heteroaryl group selected from the group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from the group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond,
- R7 is hydroxyl, or Cyc1, in which
- Cyc1 is a ring system of formula Ia



in which

- A is C (carbon),
- B is C (carbon),
- R71 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,
- R72 is hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,
- M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which
- Ar2 is a benzene ring,
- Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur,
- or a salt thereof.

3. (Previously Presented) A compound of formula I according to claim 1  
in which

- R1 is hydrogen, or 1-4C-alkyl,
- R2 is hydrogen, or 1-4C-alkyl,
- R3 is hydrogen, or 1-4C-alkyl,
- R4 is hydrogen, or 1-4C-alkyl,
- R5 is hydrogen, or 1-4C-alkyl,
- R6 is -T1-Q1, in which
- T1 is a bond, or 1-4C-alkylene,
- Q1 is Ar1, Aa1, Hh1, or Ah1, in which
- Ar1 is phenyl, or R61-substituted phenyl, in which
- R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which
- either
- T2 is a bond,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which  
 Har1 is either  
 a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or  
 a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 or  
 T2 is 1-4C-alkylene,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-4C-alkyl, or Har1-1-4C-alkyl, in which  
 Har1 is either  
 a monocyclic 5-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a monocyclic 6-membered unsaturated heteroaromatic ring comprising one or two nitrogen atoms, or  
 a fused bicyclic 9-membered unsaturated heteroaromatic ring comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, or  
 a fused bicyclic 10-membered unsaturated heteroaromatic ring comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-4C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is a biphenyl radical,  
 Hh1 is a bipyridyl, pyrazolyl-pyridinyl, imidazolyl-pyridinyl, or pyridinyl-thiophenyl radical,  
 Ah1 is a pyridinyl-phenyl, pyrazolyl-phenyl, or imidazolyl-phenyl radical,

R7 is hydroxyl, or 2-aminophenyl,  
or a salt thereof.

4. (Previously Presented) A compound of formula I according to claim 1  
in which

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is hydrogen,

R5 is hydrogen,

R6 is -T1-Q1, Aa1, Hh1, or Ah1, in which

T1 is a bond, or 1-2C-alkylene,

Q1 is Ar1, in which

Ar1 is phenyl, or R61-substituted phenyl, in which

R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which

either

T2 is a bond,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which

Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which

Het1 is morpholino,

or

T2 is 1-2C-alkylene,

R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which

Har1 is pyridinyl, benzimidazolyl, benzoxazolyl, benzofuranyl, benzothiophenyl or indolyl, and

R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,

or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which

Het1 is morpholino,

Aa1 is a biphenyl radical,

Hh1 is a bipyridyl, pyrazolyl-pyridinyl, imidazolyl-pyridinyl, or pyridinyl-thiophenyl radical,

Ah1 is a pyridinyl-phenyl, pyrazolyl-phenyl, or imidazolyl-phenyl radical,

R7 is hydroxyl, or 2-aminophenyl,

or a salt thereof.

5. (Previously Presented) A compound of formula I according to claim 1  
in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is 1-4C-alkyl, and  
 R612 is 1-4C-alkyl,  
 or  
 T2 is 1-2C-alkylene,  
 R611 is hydrogen, 1-4C-alkyl, phenyl-1-2C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is pyridinyl, or indolyl, and  
 R612 is hydrogen, 1-4C-alkyl, or hydroxy-2-3C-alkyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
 Hh1 is a pyridinyl-thiophenyl radical,  
 Ah1 is a 3-(pyridinyl)-phenyl, 3-(pyrazolyl)-phenyl, 4-(pyridinyl)-phenyl or 4-(pyrazolyl)-phenyl  
 radical,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

6. (Previously Presented) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which

Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
R61 is methyl, or -T2-N(R611)R612, in which  
either  
T2 is a bond,  
R611 is methyl, and  
R612 is methyl,  
or  
T2 is methylene,  
R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl in which  
Har1 is pyridinyl or indolyl, and  
R612 is hydrogen, methyl, or 2-hydroxy-ethyl,  
or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
heterocyclic ring Het1, in which  
Het1 is morpholino,  
Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
Hh1 is a pyridinyl-thiophenyl radical,  
Ah1 is a 3-(pyridinyl)-phenyl, 3-(pyrazolyl)-phenyl, 4-(pyridinyl)-phenyl or 4-(pyrazolyl)-phenyl  
radical,  
R7 is hydroxyl, or 2-aminophenyl,  
or a salt thereof.

7. (Previously Presented) A compound of formula I according to claim 1  
in which

R1 is hydrogen,  
R2 is hydrogen,  
R3 is hydrogen,  
R4 is hydrogen,  
R5 is hydrogen,  
R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
T1 is a bond,  
Q1 is Ar1, in which  
Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
R61 is methyl, or -T2-N(R611)R612, in which  
either  
T2 is a bond,  
R611 is methyl, and  
R612 is methyl,  
or  
T2 is methylene,

R611 is hydrogen, methyl, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl in which  
 Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and  
 R612 is hydrogen, methyl, or 2-hydroxy-ethyl,  
 or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
 Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,  
 Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl, 3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-  
 phenyl, 4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-  
 pyrazol-4-yl)-phenyl,  
 R7 is hydroxyl, or 2-aminophenyl,  
 or a salt thereof.

8. (Withdrawn) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
 R61 is methyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is methyl, and  
 R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which  
 Har1 is pyridin-3-yl, pyridin-4-yl, indol-2-yl, indol-3-yl or indol-5-yl, and  
 R612 is hydrogen,  
 or  
 T2 is methylene,  
 R611 is methyl, or 2-(Har1)-ethyl, in which  
 Har1 is indol-2-yl, and

R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is 2-(Har1)-ethyl, in which  
 Har1 is indol-2-yl, and  
 R612 is 2-hydroxy-ethyl,  
 or  
 T2 is methylene, and  
 R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
 Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,  
 Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl, 3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-  
 phenyl, 4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-  
 pyrazol-4-yl)-phenyl,  
 R7 is hydroxyl,  
 or a salt thereof.

9. (Withdrawn) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, Aa1, Hh1, Ah1, or benzyl, in which  
 T1 is a bond,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, 3-(R61)-phenyl, or 4-(R61)-phenyl, in which  
 R61 is methyl, or -T2-N(R611)R612, in which  
 either  
 T2 is a bond,  
 R611 is methyl, and  
 R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is hydrogen, isobutyl, benzyl, Har1-methyl, or 2-(Har1)-ethyl, in which  
 Har1 is pyridin-3-yl, pyridin-4-yl, indol-3-yl, or indol-5-yl, and

R612 is hydrogen,  
 or  
 T2 is methylene,  
 R611 is methyl, or 2-(Har1)-ethyl, in which  
 Har1 is indol-2-yl, and  
 R612 is methyl,  
 or  
 T2 is methylene,  
 R611 is 2-(Har1)-ethyl, in which  
 Har1 is indol-2-yl, and  
 R612 is 2-hydroxy-ethyl,  
 or  
 T2 is methylene, and  
 R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a  
 heterocyclic ring Het1, in which  
 Het1 is morpholino,  
 Aa1 is 1,1'-biphen-4-yl or 1,1'-biphen-3-yl,  
 Hh1 is 5-(pyridin-2-yl)-thiophen-2-yl,  
 Ah1 is 3-(pyridin-3-yl)-phenyl, 3-(pyridin-4-yl)-phenyl, 3-(pyrazol-1-yl)-phenyl, 3-(1H-pyrazol-4-yl)-  
 phenyl, 4-(pyridin-3-yl)-phenyl, 4-(pyridin-4-yl)-phenyl, 4-(pyrazol-1-yl)-phenyl or 4-(1H-  
 pyrazol-4-yl)-phenyl,  
 R7 is 2-aminophenyl,  
 or a salt thereof.

**10.** (Withdrawn) A compound of formula I according to claim 1  
 in which

R1 is hydrogen,  
 R2 is hydrogen,  
 R3 is hydrogen,  
 R4 is hydrogen,  
 R5 is hydrogen,  
 R6 is -T1-Q1, or biphenyl, in which  
 T1 is a bond, or 1-2C-alkylene,  
 Q1 is Ar1, in which  
 Ar1 is phenyl, or R61-substituted phenyl, in which  
 R61 is 1-4C-alkyl, or -T2-N(R611)R612, in which  
 T2 is a bond, or 1-2C-alkylene,  
 R611 is 1-4C-alkyl, or Har1-1-2C-alkyl, in which  
 Har1 is benzimidazolyl, or indolyl,

R612 is 1-4C-alkyl,  
R7 is hydroxyl, or 2-aminophenyl,  
or a salt thereof.

11. (Withdrawn) A compound of formula I according to claim 1  
in which

R1 is hydrogen,  
R2 is hydrogen,  
R3 is hydrogen,  
R4 is hydrogen,  
R5 is hydrogen,  
R6 is -T1-Q1, biphenyl, or benzyl, in which  
T1 is a bond,  
Q1 is Ar1, in which  
Ar1 is R61-substituted phenyl, in which  
R61 is methyl, dimethylamino, or -T2-N(R611)R612, in which  
T2 is methylene,  
R611 is methyl, or 2-(indol-2-yl)ethyl,  
R612 is methyl,  
R7 is hydroxyl, or 2-aminophenyl,  
or a salt thereof.

12. (Previously Presented) A compound of formula I according to claim 1 which is selected from  
the group consisting of

1. (E)-N-Hydroxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
2. N-Hydroxy-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide,
3. (E)-3-[1-(Biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
4. (E)-3-[1-(4-Dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
5. (E)-N-(2-Amino-phenyl)-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
6. (E)-N-(2-Amino-phenyl)-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide,
7. (E)-N-(2-Amino-phenyl)-3-[1-(biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
8. (E)-N-(2-Amino-phenyl)-3-[1-(4-dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
9. (E)-N-Hydroxy-3-(1-[4-(((2-(1H-indol-2-yl)-ethyl)-methyl-amino)-methyl)-benzene sulfonyl]-1H-pyrrol-3-yl)-acrylamide,
10. (E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
11. (E)-N-Hydroxy-3-[1-(4-(((pyridin-3-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
12. (E)-N-Hydroxy-3-[1-(4-(((1H-indol-3-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,

13. (E)-3-[1-[4-(Benzylamino-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
  14. (E)-N-Hydroxy-3-[1-[4-(isobutylamino-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  15. (E)-N-Hydroxy-3-[1-[4-[(1H-indol-5-ylmethyl)-amino]-methyl]-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  16. (E)-N-Hydroxy-3-[1-[4-[(pyridin-4-ylmethyl)-amino]-methyl]-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  17. (E)-3-[1-(4-Aminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
  18. (E)-N-Hydroxy-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  19. (E)-N-Hydroxy-3-[1-[4-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  20. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  21. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  22. (E)-N-(2-Amino-phenyl)-3-[1-[4-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  23. (E)-3-[1-(Biphenyl-3-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide,
  24. (E)-N-Hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  25. (E)-N-Hydroxy-3-[1-(4-pyrazol-1-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  26. (E)-N-(2-Amino-phenyl)-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  27. (E)-N-Hydroxy-3-[1-(4-morpholin-4-ylmethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  28. (E)-N-Hydroxy-3-[1-[4-[(2-hydroxy-ethyl)-[2-(1H-indol-2-yl)-ethyl]-amino]-methyl]-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  29. (E)-N-Hydroxy-3-[1-(3-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  30. (E)-N-(2-Amino-phenyl)-3-[1-(3-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  31. (E)-N-(2-Amino-phenyl)-3-[1-(3-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide,
  32. (E)-N-Hydroxy-3-[1-[3-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
  33. (E)-N-(2-Amino-phenyl)-3-[1-[3-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide,
- and the salts thereof.

13. (Cancelled)

14. (Previously Presented) A pharmaceutical composition comprising one or more compounds of formula I as claimed in claim 1, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient and/or vehicle.

15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

**18.** (Withdrawn and Currently Amended) A method for treating a disease in a patient<sub>1</sub> comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1 [1] or a pharmaceutically acceptable salt thereof.

**19.** (Withdrawn and Currently Amended) A method for treating benign and/or malignant neoplasia [1] in a patient<sub>1</sub> comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1 [1] or a pharmaceutically acceptable salt thereof.

**20.** (Withdrawn and Currently Amended) A method for treating a non-malignant disease [1] in a patient<sub>1</sub> comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1 [1] or a pharmaceutically acceptable salt thereof.

**21.** (Withdrawn and Currently Amended) A method for treating a disease responsive or sensitive to inhibition of histone deacetylase activity in a patient<sub>1</sub> comprising administering to said patient a therapeutically effective and tolerable amount of a compound of formula I as claimed in claim 1 [1] or a pharmaceutically acceptable salt thereof.

**22.** (Withdrawn) The method according to claim 19, wherein the benign and/or malignant neoplasia is cancer.

**23.** (Withdrawn) The method according to claim 20, wherein the non-malignant disease is selected from the group consisting of arthropathies, osteopathological conditions, systemic lupus erythematosus, rheumatoid arthritis, smooth muscle cell proliferation, vascular proliferative disorders, atherosclerosis, restenosis and inflammatory conditions.

**24.** (Withdrawn) The method according to claim 19, wherein the compound of formula I is administered simultaneously, sequentially or separately with one or more further therapeutic agents.

**25.** (Withdrawn) The method according to claim 20, wherein the compound of formula I is administered simultaneously, sequentially or separately with one or more further therapeutic agents.

**26.** (New) A compound of formula I according to claim 1, which is

1. (E)-N-Hydroxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
2. N-Hydroxy-3-(1-phenylmethanesulfonyl-1H-pyrrol-3-yl)-acrylamide
3. (E)-3-[1-(Biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
4. (E)-3-[1-(4-Dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
7. (E)-N-(2-Amino-phenyl)-3-[1-(biphenyl-4-sulfonyl)-1H-pyrrol-3-yl]-acrylamide or
8. (E)-N-(2-Amino-phenyl)-3-[1-(4-dimethylamino-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide

or a salt thereof.

27. (New) A compound of formula I according to claim 1, which is

9. (E)-N-Hydroxy-3-(1-[4-((2-(1H-indol-2-yl)-ethyl)-methyl-amino)-methyl]-benzene sulfonyl]-1H-pyrrol-3-yl)-acrylamide
10. (E)-3-[1-(4-Dimethylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
11. (E)-N-Hydroxy-3-[1-(4-(((pyridin-3-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
12. (E)-N-Hydroxy-3-[1-(4-(((1H-indol-3-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
13. (E)-3-[1-[4-(Benzylamino-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
14. (E)-N-Hydroxy-3-[1-[4-(isobutylamino-methyl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
15. (E)-N-Hydroxy-3-[1-(4-(((1H-indol-5-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
16. (E)-N-Hydroxy-3-[1-(4-(((pyridin-4-ylmethyl)-amino)-methyl)-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
17. (E)-3-[1-(4-Aminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
18. (E)-N-Hydroxy-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
19. (E)-N-Hydroxy-3-[1-[4-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
20. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-4-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
21. (E)-N-(2-Amino-phenyl)-3-[1-(4-pyridin-3-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
22. (E)-N-(2-Amino-phenyl)-3-[1-[4-(1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide
23. (E)-3-[1-(Biphenyl-3-sulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide
24. (E)-N-Hydroxy-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
25. (E)-N-Hydroxy-3-[1-(4-pyrazol-1-yl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide
26. (E)-N-(2-Amino-phenyl)-3-[1-(5-pyridin-2-yl-thiophene-2-sulfonyl)-1H-pyrrol-3-yl]-acrylamide
27. (E)-N-Hydroxy-3-[1-(4-morpholin-4-ylmethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-acrylamide or
28. (E)-N-Hydroxy-3-[1-[4-((2-hydroxy-ethyl)-[2-(1H-indol-2-yl)-ethyl]-amino)-methyl]-benzenesulfonyl]-1H-pyrrol-3-yl]-acrylamide

or a salt thereof.